NBSE
Price:
$0.378
Market Cap:
$1.42M
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pi...[Read more]
Industry
Biotechnology
IPO Date
2004-05-28
Stock Exchange
NASDAQ
Ticker
NBSE
According to NeuBase Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.02. This represents a change of -93.53% compared to the average of -0.31 of the last 4 quarters.
The mean historical PE Ratio of NeuBase Therapeutics, Inc. over the last ten years is -6.96. The current -0.02 PE Ratio has changed -70.78% with respect to the historical average. Over the past ten years (40 quarters), NBSE's PE Ratio was at its highest in in the June 2023 quarter at -0.23. The PE Ratio was at its lowest in in the March 2014 quarter at -34.98.
Average
-6.96
Median
-3.64
Minimum
-26.84
Maximum
-0.37
Discovering the peaks and valleys of NeuBase Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 466.17%
Maximum Annual PE Ratio = -0.37
Minimum Annual Increase = -90.24%
Minimum Annual PE Ratio = -26.84
Year | PE Ratio | Change |
---|---|---|
2022 | -0.37 | -90.24% |
2021 | -3.84 | -55.48% |
2020 | -8.63 | 466.17% |
2019 | -1.52 | 86.24% |
2018 | -0.82 | -39.56% |
2017 | -1.35 | -60.68% |
2016 | -3.44 | -33.25% |
2015 | -5.16 | -70.66% |
2014 | -17.58 | -34.50% |
2013 | -26.84 | -14.58% |
The current PE Ratio of NeuBase Therapeutics, Inc. (NBSE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.28
5-year avg
-3.04
10-year avg
-6.96
NeuBase Therapeutics, Inc.’s PE Ratio is greater than Immix Biopharma, Inc. (-2.39), less than CNS Pharmaceuticals, Inc. (-0.00), less than eFFECTOR Therapeutics, Inc. (-0.00), less than Navidea Biopharmaceuticals, Inc. (0.01), greater than Sonnet BioTherapeutics Holdings, Inc. (-2.73), less than Kiromic BioPharma, Inc. (0), greater than ZyVersa Therapeutics, Inc. (-0.08), greater than YS Biopharma Co., Ltd. (-0.07), greater than BiomX Inc. (-2.21), greater than Landos Biopharma, Inc. (-0.27), greater than Apexigen, Inc. (-5.74), greater than Angion Biomedica Corp. (-0.36), greater than Monte Rosa Therapeutics, Inc. (-0.24), greater than NewAmsterdam Pharma Company N.V. (-4.83), greater than Inventiva S.A. (-7.41), greater than Cullinan Oncology, Inc. (-1.12), greater than Compass Therapeutics, Inc. (-6.16), greater than null (-5.11),
Company | PE Ratio | Market cap |
---|---|---|
-2.39 | $43.37M | |
-0.00 | $3.98M | |
-0.00 | $1.88K | |
0.01 | $50.04K | |
-2.73 | $2.96M | |
0 | $1.73M | |
-0.08 | $1.96M | |
-0.07 | $192.09M | |
-2.21 | $13.04M | |
-0.27 | $71.68M | |
-5.74 | $9.57M | |
-0.36 | $30.11M | |
-0.24 | $542.54M | |
-4.83 | $1.62B | |
-7.41 | $239.85M | |
-1.12 | $922.99M | |
-6.16 | $233.90M | |
-5.11 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NeuBase Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NeuBase Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is NeuBase Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for NeuBase Therapeutics, Inc. (NBSE)?
What is the highest PE Ratio for NeuBase Therapeutics, Inc. (NBSE)?
What is the 3-year average PE Ratio for NeuBase Therapeutics, Inc. (NBSE)?
What is the 5-year average PE Ratio for NeuBase Therapeutics, Inc. (NBSE)?
How does the current PE Ratio for NeuBase Therapeutics, Inc. (NBSE) compare to its historical average?